

P&T Motion History Diabetes - GLP-1 Agonists

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
albiglutide dulaglutide exenatide exenatide ER liraglutide liraglutide + insulin degludec lixisenatide lixisenatide + insulin glargine semaglutide	<p>After considering the evidence of safety, efficacy and special populations for the treatment of diabetes, I move that GLP-1 Agonists dulaglutide, exenatide, exenatide ER, liraglutide, lixisenatide, semaglutide, and all combinations listed in this sub-class are safe and efficacious.</p> <p>GLP-1 Agonist can be subject to therapeutic interchange in the Washington preferred drug list. Therapeutic interchange is allowed only within each diabetes sub-class.</p> <p>At least one drug with cardiovascular benefits needs to be preferred on the PDL for patients with proven cardiovascular disease.</p> <p>Albiglutide cannot be preferred on the PDL.</p> <p>Motion: Storhaug 2nd: Brown</p>	June 15, 2022	Yes Schwilke Park	Yes Chawla Schwilke	Passed unanimous